Materiały źródłowe

• #1 Cryoglobulinemia: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/13204-cryoglobulinemia

  Cryoglobulinemia treatment depends on the organs it affects, the degree of damage and the presence of other medical conditions. Its very important not only to treat cryoglobulinemia but also to address any other associated disorders. When you treat your other conditions, the symptoms of cryoglobulinemia may improve. […] For mild cases of cryoglobulinemia, your healthcare provider may recommend over-the-counter (OTC) anti-inflammatory drugs (NSAIDs) for pain, along with avoiding cold temperatures. Theyll want to monitor your disease with regular checkups. […] For more moderate to severe cases of cryoglobulinemia, treatments may include: […] Immunosuppressive drugs: The mainstay of treatment is corticosteroids such as prednisone, with or without other medications, depending on the affected organ and the extent of involvement.

• #1 Cryoglobulinemia Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/cryoglobulinemia

  MILD OR MODERATE FORMS OF CRYOGLOBULINEMIA CAN OFTEN BE TREATED BY TAKING STEPS TO DEAL WITH THE UNDERLYING CAUSE. […] CURRENT DIRECT-ACTING MEDICINES FOR HEPATITIS C ELIMINATE THE VIRUS IN NEARLY ALL PEOPLE. AS HEPATITIS C GOES AWAY, THE CRYOGLOBULINS WILL DISAPPEAR IN ABOUT ONE HALF OF ALL PEOPLE OVER THE NEXT 12 MONTHS. YOUR PROVIDER WILL CONTINUE TO MONITOR THE CRYOGLOBULINS AFTER TREATMENT. […] SEVERE CRYOGLOBULINEMIA VASCULITIS INVOLVES VITAL ORGANS OR LARGE AREAS OF SKIN. IT IS TREATED WITH CORTICOSTEROIDS AND OTHER MEDICINES THAT SUPPRESS THE IMMUNE SYSTEM. […] RITUXIMAB IS AN EFFECTIVE DRUG AND HAS FEWER RISKS THAN OTHER MEDICINES. […] CYCLOPHOSPHAMIDE IS USED IN LIFE-THREATENING CONDITIONS WHERE RITUXIMAB IS NOT WORKING OR AVAILABLE. THIS MEDICINE WAS USED MORE OFTEN IN THE PAST.

• #1 Cryoglobulinemia – Wikipedia

  https://en.wikipedia.org/wiki/Cryoglobulinemia

  People affected by the severest, often life-threatening, complications of cryoglobulinemic disease require urgent plasmapharesis and/or plasma exchange in order to rapidly reduce the circulating levels of their cryoglobulins. Complications commonly requiring this intervention include: hyperviscosity disease with severe symptoms of neurological (e.g., stroke, mental impairment, and myelitis) and/or cardiovascular (e.g., congestive heart failure, myocardial infarction) disturbances; vasculitis-driven intestinal ischemia, intestinal perforation, cholecystitis, or pancreatitis, causing acute abdominal pain, general malaise, fever, and/or bloody bowel movements; vasculitis-driven pulmonary disturbances (e.g., coughing up blood, acute respiratory failure, X-ray evidence of diffuse pulmonary infiltrates caused by diffuse alveolar hemorrhage); and severe kidney dysfunction due to intravascular deposition of immunoglobulins or vasculitis. Along with this urgent treatment, severely symptomatic patients are commonly started on therapy to treat any underlying disease; this treatment is often supplemented with anti-inflammatory drugs such as corticosteroids (e.g., dexamethasone) and/or immunosuppressive drugs. Cases where no underlying disease is known are also often treated with the latter corticosteroid and immunosuppressive medications.

• #1 Cryoglobulins: An Important but Neglected Clinical Test

  https://www.annclinlabsci.org/content/36/4/395.full

  Cryoglobulin (CR) denotes a serum immunoglobulin that precipitates at temperatures below 37C and dissolves on re-warming. Treatment depends on the symptoms and causes, and on the phenotyping of the CR. Considering the high incidence of CR in diseases such as hepatitis C virus (HCV) infection, together with the high worldwide prevalence of this disease, it is clear that testing for CR is underutilized in clinical practice. […] The treatment of cryoglobulinemia depends on the severity of symptoms, the underlying disease, and the type of CR. The goal of therapy is to limit in vivo precipitation of cryoglobulins and the resultant inflammatory effects. Asymptomatic patients usually do not need treatment, even in the presence of high cryocrit levels. Some patients with cryoglobulinemia suffer from mild, recurrent episodes of lower extremity purpura that require no specific therapy or only therapy with general anti-inflammatory drugs (eg, ibuprofen, aspirin) or low doses of steroids.

• #1 Cryoglobulinemia: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000540.htm

  A treatment called plasmapheresis is also used. In this procedure, blood plasma is taken out of blood circulation and abnormal cryoglobulin antibody proteins are removed. The plasma is replaced by fluid, protein, or donated plasma. […] TYPE I CRYOGLOBINEMIA […] This disorder is due to a cancer of the blood or immune system such as multiple myeloma. Treatment is directed against the abnormal cancer cells that produce the cryoglobulin.

• #1 Cryoglobulinemia Treatment & Management: Approach Considerations, Medical Care, Consultations

  https://emedicine.medscape.com/article/329255-treatment

  Treatment of cryoglobulinemia varies according to the disease type and should be tailored according to clinical severity, underlying conditions, and prior therapies. The goal of therapy is to treat underlying conditions, as well as to limit the precipitant cryoglobulin and the resultant inflammatory effects. […] Asymptomatic cryoglobulinemia does not require treatment. Some authors recommend intervening as little as possible except when faced with severe deterioration of renal or neurologic function. […] Secondary cryoglobulinemia is best managed with treatment of the underlying malignancy or associated disease. Otherwise, cryoglobulinemia is treated simply with suppression of the immune response. A paucity of controlled studies evaluating the relative efficacy of various therapies limits the use of existing data.

• #1 Cryoglobulinemic Vasculitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/cryoglobulinemic-vasculitis/

  Immunosuppressive drugs are the mainstay of treatment for severe disease where vital organs are affected. Glucocorticoids such as prednisone, azathioprine, and cyclophosphamide are widely used. […] Biologic drugs such as rituximab are a common treatment option for this condition. Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation. […] Plasmapheresis is an option when patients have life-threatening or organ-threatening cryoglobulinemic vasculitis. This procedure filters clumps of cryoglobulins from the blood plasma, helping to prevent cryoglobulins from blocking the arteries and restricting blood flow to organs. […] Relapses can occur, so follow-up care is essential. […] The medications used to treat cryoglobulinemic vasculitis have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important.

• #1 Medications Used to Treat Cryoglobulinemia – Alliance for Cryoglobulinemia

  https://allianceforcryo.org/cryoglobulinemia/medications-used-to-treat-cryo/

  Some cryo patients achieve prolonged periods of remission through the use of medications. During these periods the signs or symptoms of the disease are absent. […] In the case of Essential Mixed Cryoglobulinemia, remission periods may be obtained. […] Deciding to take immune-suppressing drugs is a difficult choice that should be discussed with your doctor. […] Plasmapheresis has also been used in conjunction with drugs to improve symptoms. […] For example, using cyclophosphamide with prednisone to force remission in a case of cryo is not unusual. Once remission is established, one can transition to something like Imuran, methotrexate, or CellCept. […] Some people respond very well to Imuran, making it a good choice with less risk compared to staying on cyclophosphamide. […] Also, Imuran is a reasonably safe drug to stay on if you have to take it long-term.

• #1 Cryoglobulinemia Treatment & Management: Approach Considerations, Medical Care, Consultations

  https://emedicine.medscape.com/article/329255-treatment

  Uncontrolled studies suggest that rituximab is effective in controlling disease manifestations such as vasculitis, peripheral neuropathy, arthralgias, low-grade B-cell lymphomas, renal disease, and fever. […] Rituximab therapy has been used predominantly in HCV-related mixed cryoglobulinemia refractory to or unsuitable for corticosteroids and antiviral (IFN-alfa) therapy. […] In patients with relapsing mixed cryoglobulinemia vasculitis, low-dose rituximab proved effective, safe, and cost-effective for long-term management. […] Other potential therapies for refractory cryoglobulinemic vasculitis include mycophenolate mofetil and belimumab. However, tumor necrosis factor (TNF) inhibitors are not effective.

• #1 Cryoglobulinemia: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/13204-cryoglobulinemia

  Antiviral medications: If your provider found another medical condition like hepatitis C, they may recommend antiviral therapy. They may also refer you to a hepatologist (liver specialist). […] Biologics: The biologic rituximab is a common treatment for cryoglobulinemia. Biologics are complex proteins derived from living organisms that target certain parts of your immune system to control inflammation. […] Plasmapheresis: Another form of treatment that decreases the amount of cryoglobulins in your blood. This procedure, called plasmapheresis, removes cryoglobulins from your plasma (the liquid in your blood). This helps prevent cryoglobulins from clogging your arteries, which could block your blood flow and lead to organ damage. […] The medications your healthcare provider recommends for the treatment of cryoglobulinemia may cause serious side effects. These side effects include potential bone loss (osteoporosis) and lowering your bodys ability to fight infection. Because of this, its important to see your provider for routine checkups. They may be able to prescribe medications to offset the side effects. Its also important to prevent infection, so talk to your provider about vaccinations to lower your risk of infection.

• #1

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  RTX has been studied in two randomized controlled clinical trials of the treatment of cryoglobulinemic vasculitis in patients with and without HCV-associated disease, and was shown to be superior when compared to conventional immunosuppressive therapies. […] The primary endpoint, survival at 12 months, was higher in the RTX group. […] In the second study, the primary endpoint, remission at study month 6, was reached in 83 % of the RTX group compared with 8.3 % of the control group. […] The treatment of non-HCV-related cryoglobulinemic vasculitis is not well defined. […] Plasma exchange is not commonly used for the treatment of cryoglobulinemic vasculitis. […] In these situations, it can be used as a bridge to treatment of the underlying disease or initiation of immunosuppressive agents such as rituximab.

• #1 Cryoglobulinemia Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/329255-guidelines

  In 2023, the Italian Study Group of Cryoglobulinemia (GISC) released consensus based guidelines for the management of mixed cryoglobulinemia which included the following key recommendations: […] Overall, rituximab is effective in the management of severe, but not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis. […] Rituximab is effective in the management of glomerulonephritis, peripheral neuropathy and skin ulcers associated with cryoglobulinemic vasculitis. […] Rituximab is effective in the management of less severe manifestations (purpura, arthralgia, fatigue) of cryoglobulinemic vasculitis. […] Rituximab may be effective in the management of both infectious and non-infectious cryoglobulinemic vasculitis. […] Retreatment of severe, but not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis of a clinical relapse after the first cycle of rituximab is effective.

• #1 Cryoglobulinemia Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/329255-guidelines

  Rituximab given at low doses (250 mg/mq weekly for 2 weeks) is equally effective as given at high doses (375 mg/mq/weekly for 4 weeks or 1 g 2 weeks apart) in selected cases of cryoglobulinemic vasculitis. […] Maintenance treatment with rituximab is required in severe or life-threatening cryoglobulinemic vasculitis.

• #1 Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9873783/

  Rituximab shows a steroid-sparing effect in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B). […] Rituximab does not usually carry an increased risk of serious adverse events compared to other immunosuppressants or high-dose glucocorticoids. […] Rituximab given alone is not associated with an increased risk of hepatitis C reactivation, even if a transient elevation of the viral load can be seen (LoE 1B). […] The risk of severe infusion reactions during rituximab administration is very low (LoE 1A). […] Rituximab is effective and safe in combination with antivirals in some cases of cryoglobulinemic vasculitis (LoE 5C). […] Rituximab is effective in patients with HCV-related cryoglobulinemic vasculitis showing persistent and severe clinical course, despite virological clearance by antivirals (LoE 5C). […] Maintenance treatment with rituximab is required in severe or life-threatening cryoglobulinemic vasculitis (LoE 5C).

• #1 Cryoglobulinemia Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/329255-guidelines

  Rituximab should be used with caution in patients carrying latent HBV infection; Adequate prophylactic therapy for HBV infection, or monitoring HBV DNA or HBsAg title should be done. […] Rituximab does not usually carry an increased risk of serious adverse events compared to other immunosuppressants or high-dose glucocorticoids. […] Rituximab given alone is not associated with an increased risk of HCV reactivation, even if a transient elevation of the viral load is present. […] The risk of severe infusion reactions during rituximab administration is very low. […] Rituximab is effective and safe for use in combination with antivirals in some cases of cryoglobulinemic vasculitis. […] Rituximab is effective in patients with HCV-related cryoglobulinemic vasculitis showing persistent and severe clinical course.

• #1

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  While PEG-IFN-based regimens show clinical efficacy, their inability to induce a complete clinical and virologic response in many patients indicates that other therapeutic options are needed. […] More recently, treatment options have expanded with the addition of first-generation protease inhibitors (boceprevir or telaprevir). […] Current interferon-free regimens include ledipasvir-sofosbuvir without ribavirin, elbasvir-grazoprevir with or without ribavirin, ombitasvir-paritaprevir-ritonavir plus dasabuvir with or without ribavirin, simeprevir plus sofosbuvir with or without ribavirin, and daclatasvir plus sofosbuvir. […] This favorable response profile has led to interest in the study of these regimens in patients with HCV-related cryoglobulinemic vasculitis. […] Some experts recommend delaying the initiation of antiviral therapy in patients with severe manifestations of cryoglobulinemic vasculitis for one to four months after initiation of immunosuppression.

• #1 Cryoglobulinemia | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/20147

  HCV infections most commonly cause mixed cryoglobulinemia. The connection between infection and autoimmune or lymphoproliferative disorders is common. The general onset of this disease is slow-paced, but in some situations, rapid progression can occur. In recent years, with the advent of direct antiviral therapy, there has been a change in the treatment approach. HCV-positive patients with cryoglobulinemia are now recommended to receive initial therapy with pan-genotypic antiviral regimens (such as sofosbuvir or velpatasvir and glecaprevir or pibrentasvir). […] Studies have demonstrated a response rate with minimal viral counts in almost 100% of patients, although about 13% experience a relapse. […] The administration of antivirals in HCV-B-cell clonalities is necessary to eliminate the viral threat, especially considering the immunosuppressives used to obliterate the clone. Direct antiviral agents have a better tolerability and safety profile than interferon (IFN), with the latter exhibiting a superior anti-lymphoma effect.

• #1 Cryoglobulinemia | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/20147

  However, its use comes with potential toxicities, such as life-threatening vasculitis flares, serum sickness syndrome, and exacerbation of HCV viremia. […] Presently, apheresis is considered a second-line treatment option for cryoglobulinemic vasculitis. […] However, as outlined below, apheresis is crucial in severe conditions, which include the following: Hyperviscosity syndrome (especially with a cryocrit exceeds 10%), skin ulcers caused by cutaneous vasculitis, life-threatening, multiorgan cryoglobulinemic vasculitis, rapidly progressing renal failure, refractory neuropathy. […] For apheresis, the recommended course typically involves daily exchanges approximately 3 times per week over a couple of weeks. […] Steroids and cyclophosphamide are frequently administered alongside apheresis to mitigate the risk of a post-apheresis rebound in cryoglobulin production. […] Patients undergoing immunosuppressive treatments for cryoglobulinemia necessitate close monitoring, the extent of which hinges on the severity of the condition.

• #1 Cryoglobulinemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557606/

  However, its use comes with potential toxicities, such as life-threatening vasculitis flares, serum sickness syndrome, and exacerbation of HCV viremia. […] Presently, apheresis is considered a second-line treatment option for cryoglobulinemic vasculitis. […] However, as outlined below, apheresis is crucial in severe conditions, which include the following: Hyperviscosity syndrome (especially with a cryocrit exceeds 10%), skin ulcers caused by cutaneous vasculitis, life-threatening, multiorgan cryoglobulinemic vasculitis, rapidly progressing renal failure, refractory neuropathy. […] Steroids and cyclophosphamide are frequently administered alongside apheresis to mitigate the risk of a post-apheresis rebound in cryoglobulin production. […] Patients undergoing immunosuppressive treatments for cryoglobulinemia necessitate close monitoring, the extent of which hinges on the severity of the condition.

• #1 Cryoglobulinemia – Wikipedia

  https://en.wikipedia.org/wiki/Cryoglobulinemia

  Treatment of Type I disease is generally directed towards treating the underlying pre-malignant or malignant disorder (see plasma cell dyscrasia, Waldenstrm’s macroglobulinemia, and chronic lymphocytic leukemia). This involves appropriate chemotherapy regimens which may include bortezomib (promotes cell death by apoptosis in cells accumulating immunoglobulins) in patients with monoclonal immunoglobulin-induced kidney failure and rituximab (antibody directed against CD20 surface antigen-bearing lymphocytes) in patients with Waldenstroms macroglobulinemia. […] Treatment of mixed cryoglobulinemic disease is, similar to type I disease, directed toward treating any underlying disorder. This includes malignant (particularly Waldenstrm’s macroglobulinemia in type II disease), infectious, or autoimmune diseases in type II and III disease. Recently, evidence of hepatitis C infection has been reported in the majority of mixed disease cases with rates being 70-90% in areas with high incidences of hepatitis C. The most effective therapy for hepatitis C-associated cryoglobulinemic disease consists of a combination of anti-viral drugs, pegylated INF and ribavirin; depletion of B cells using rituximab in combination with antiviral therapy or used alone in patients refractory to antiviral therapy has also proven successful in treating the hepatitis C-associated disease. Data on the treatment of infectious causes other than hepatitis C for mixed disease are limited. A current recommendation treats the underlying disease with appropriate antiviral, anti-bacterial, or anti-fungal agents, if available; in cases refractory to an appropriate drug, the addition of immunosuppressive drugs to the therapeutic regimen may improve results. Mixed cryoglobulinemic disease associated with autoimmune disorders is treated with immunosuppressive drugs: a combination of a corticosteroid with either cyclophosphamide, azathioprine, or mycophenolate or combination of a corticosteroid with rituximab have been used successfully to treated mixed disease associated with autoimmune disorders.

• #1 Cryoglobulinemia: Better Treatments With Brighter Outcomes

  https://www.cancernetwork.com/view/cryoglobulinemia-better-treatments-brighter-outcomes

  The outcome for patients with cryoglobulinemia has improved since the recognition that the condition is frequently associated with HCV and that elimination of this virus has therapeutic benefit for affected patients. […] The goal of the management of type I cryoglobulinemia in the setting of malignant disease is to eliminate the malignant B-cell clone that is producing the offending Ig through the use of effective anticancer treatment. Patients with MGUS are often managed with glucocorticosteroids, although the antiB-cell antibody rituximab has been used, as has plasmapheresis; bortezomib has been tried as well. […] The treatment of patients with virally associated mixed cryoglobulinemia has focused on combination therapy with antiviral drugs to eliminate the offending HCV and its associated cryoglobulinemic-inducing proteins. Most patients receive ribavirin along with pegylated interferon-alfa, and the majority have good responses.

• #1 Cryoglobulinemia and Multiple Myeloma: Treatment and Outlook

  https://www.healthline.com/health/multiple-myeloma/cryoglobulinemia-and-multiple-myeloma

  Treatment for cryoglobulinemia is only necessary if you have symptoms. […] Current treatments typically focus on the underlying cancer. […] In the 2017 study of 102 people with type 1 cryoglobulinemia, 73 people received treatment. Treatment was broadly divided into the following categories: steroids alone, steroids with chemotherapy drugs called alkylating agents, the targeted therapy drug rituximab (Rituxan) with or without steroids, rituximab and alkylating agents with or without steroids, new myeloma drugs, including immunomodulatory drugs and proteasome inhibitors, other therapies, such as antimetabolites like azathioprine and methotrexate. […] The researchers in this study found that symptoms improved in about 80 percent of those who received treatment. Only 21 percent experienced no response to treatment.

• #1 Mixed cryoglobulinemia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-25

  Mixed cryoglobulinemia (MC), type II and type III, refers to the presence of circulating cryoprecipitable immune complexes in the serum and manifests clinically by a classical triad of purpura, weakness and arthralgias. […] The first-line treatment of MC should focus on eradication of HCV by combined interferon-ribavirin treatment. […] Pathogenetic treatments (immunosuppressors, corticosteroids, and/or plasmapheresis) should be tailored to each patient according to the progression and severity of the clinical manifestations. […] Long-term monitoring is recommended in all MC patients to assure timely diagnosis and treatment of the life-threatening complications. […] In patients with 'essential’ MC the immunosuppressive treatment, i.e. cyclophosphamide or rituximab, is still the first-line intervention.

• #1 Mixed cryoglobulinemia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-25

  For HCV-associated MC, immunomodulating/immunosuppressive treatments should be considered, especially in patients with more severe complications. […] Plasma exchange is particularly useful in severe MC complications such as active membranoproliferative glomerulonephritis. […] In clinical practice, MC treatment should be tailored for the single patient according to the severity of clinical symptoms. […] Therefore, patients with severe vasculitic manifestations must be promptly treated with high doses of steroids and/or plasma exchange and/or cyclophosphamide or rituximab. […] Some recent clinical studies suggested that sequential or combined antiviral/immunosuppressive treatment could represent a rather useful therapeutic strategy. […] The overall prognosis is worse in patients with renal disease, liver failure, lymphoproliferative disease, and malignancies.

• #1 Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9873783/

  Overall, rituximab is effective (and safe) on the severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 1A). […] In particular, rituximab is effective (and safe) on the glomerulonephritis of cryoglobulinemic vasculitis (LoE 2B). […] In particular, rituximab is effective (and safe) on the peripheral neuropathy of cryoglobulinemic vasculitis (LoE 2C). […] In particular, rituximab is effective (and safe) on the skin ulcers of cryoglobulinemic vasculitis (LoE 1A). […] Rituximab is equally effective on other, not severe manifestations (purpura, arthralgia, fatigue) of cryoglobulinemic vasculitis (LoE 2B). […] Rituximab may be equally effective in infectious and non-infectious cryoglobulinemic vasculitis (LoE 5C). […] Re-treatment at clinical relapse with rituximab, after the first cycle, is effective (and safe) in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B).

• #1 Cryoglobulinemia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/cryoglobulinemia/diagnosis-treatment/drc-20449756

  Treatment depends on the cause of cryoglobulinemia and how bad it is. Watchful waiting might be a choice if you have no symptoms. Treatment may include medicines that calm the immune system or fight viral infections. For severe symptoms, a treatment that swaps blood plasma for donor plasma or another fluid might be used. […] Even with treatment, cryoglobulinemia often returns. You might need regular follow-up visits with your health care professional to watch for its return.

• #1

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  The decision to initiate or continue plasma exchange should be based on the patients disease severity and therapeutic response. […] This study indicates that low-dose IL-2 use can be therapeutic for mixed cryoglobulinemia due to HCV, and indicates a new possible avenue of therapy modulating the immune response to the virus instead of targeting the virus itself. […] Antiviral therapies may be curative for HCV-associated cryoglobulinemic vasculitis if HCV eradication is achieved in the patient. […] Immunosuppressive agents such as rituximab continue to have an important adjunctive role, especially for patients with organ- or life-threatening disease, and may be initiated prior to antiviral therapy. […] Plasmapheresis can also be used as a bridge to more definitive therapies during flares of severe disease.

• #1 Cryoglobulinemic Disease

  https://www.cancernetwork.com/view/cryoglobulinemic-disease

  While there remain three main broad treatment strategies for cryoglobulinemia (conventional immunosuppression, antiviral treatment, and biologic therapy), the most recent studies suggest a change in the therapeutic approach from monotherapy to combined/sequential regimens, including both etiologic- and pathologic-driven therapies, the aim of which is to block the different etiopathogenic pathways involved.

• #1 Cryoglobulinemia Treatment Market Size & Forecast 2025-2035

  https://www.futuremarketinsights.com/reports/cryoglobulinemia-treatment-market

  Plasmapheresis is a useful adjunct to treatment in life-threatening complications of the patient since it rapidly reduces circulating cryoglobulins and immune complexes from the circulation. […] The only issue with high prices is the costliness of biologics, and insurers and hospitals look for reimbursement programs and patient support programs. […] Biologic drugs are all found to be effective autoimmune disease therapies, like cryoglobulinemia, but at very high expense, and it is one that acts as a barrier to access everywhere. […] Precision medicine, in which treatment is individualized for every patient based on their molecular and genetic profiles, has a huge potential to maximize treatment outcomes of autoimmune diseases, including of cryoglobulinemia. […] Mixed cryoglobulinemia (Type II Type III) has the highest market share in the market for the treatment of cryoglobulinemia because of its increasing prevalence and multifactorial etiology, most commonly with chronic infections such as hepatitis C. […] Antiviral drugs are the preferred treatment for cryoglobulinemia, particularly for HCV infection. […] Biologic agents like monoclonal antibodies rituximab are experiencing unprecedented growth in the market for the treatment of cryoglobulinemia.

• #1 Cryoglobulinemic Vasculitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/cryoglobulinemic-vasculitis/

  Regular doctor visits and ongoing monitoring are important in detecting relapses and preventing ongoing complications. If your symptoms return or you develop new ones, report them to your doctor as soon as possible. […] Effective treatment of cryoglobulinemic vasculitis may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #1 FAQ – Alliance for Cryoglobulinemia

  https://allianceforcryo.org/faq/

  Cryoglobulinemia can affect many areas of the body. People with cryoglobulinemia are treated by rheumatologists, dermatologists, hematologist/oncologists, ophthalmologist, nephrologists, neurologists, and cardiologists. Your principal physician will vary depending on your dominant symptoms and the healthcare system you utilize. […] By depleting the B cells which produce antibodies (including antibodies), Rituximab has greatly helped my patients with cryoglobulinemia. […] Treat the underlying when possible, and that can decrease cryoglobulins. For example, there is now a good treatment/cure for Hepatitis C. […] Keeping warm often is not enough. Immune suppression decreases cryo production and is justified for significant tissue inflammation e.g. vasculitis.

• #1 UT Health Austin | Cryoglobulinemia

  https://uthealthaustin.org/conditions/cryoglobulinemia

  Like all forms of vasculitis, corticosteroids like prednisone can be used to address the inflammation associated with cryoglobulinemia. Your physician may also use a biologic drug called rituximab. […] At UT Health Austin, we take a multidisciplinary approach to your care. This means you will benefit from the expertise of multiple specialists across a variety of disciplines caring for you in one place. The Vasculitis Clinic care team includes rheumatologists, nurses, and medical assistants who work together to help you get back to the things in your life that matter most to you. […] We collaborate with our colleagues at the Dell Medical School and The University of Texas at Austin to utilize the latest research, diagnostic, and treatment techniques, allowing us to develop the best treatment plan for you. Advanced imaging and lab testing are also available on-site if needed, including computed tomography angiography (CTA) and magnetic resonance angiography (MRA).

• #2 Cryoglobulinemia Treatment & Management: Approach Considerations, Medical Care, Consultations

  https://emedicine.medscape.com/article/329255-treatment

  Treatment of cryoglobulinemia varies according to the disease type and should be tailored according to clinical severity, underlying conditions, and prior therapies. The goal of therapy is to treat underlying conditions, as well as to limit the precipitant cryoglobulin and the resultant inflammatory effects. […] Asymptomatic cryoglobulinemia does not require treatment. Some authors recommend intervening as little as possible except when faced with severe deterioration of renal or neurologic function. […] Secondary cryoglobulinemia is best managed with treatment of the underlying malignancy or associated disease. Otherwise, cryoglobulinemia is treated simply with suppression of the immune response. A paucity of controlled studies evaluating the relative efficacy of various therapies limits the use of existing data.

• #2 Cryoglobulinemia Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/cryoglobulinemia

  MILD OR MODERATE FORMS OF CRYOGLOBULINEMIA CAN OFTEN BE TREATED BY TAKING STEPS TO DEAL WITH THE UNDERLYING CAUSE. […] CURRENT DIRECT-ACTING MEDICINES FOR HEPATITIS C ELIMINATE THE VIRUS IN NEARLY ALL PEOPLE. AS HEPATITIS C GOES AWAY, THE CRYOGLOBULINS WILL DISAPPEAR IN ABOUT ONE HALF OF ALL PEOPLE OVER THE NEXT 12 MONTHS. YOUR PROVIDER WILL CONTINUE TO MONITOR THE CRYOGLOBULINS AFTER TREATMENT. […] SEVERE CRYOGLOBULINEMIA VASCULITIS INVOLVES VITAL ORGANS OR LARGE AREAS OF SKIN. IT IS TREATED WITH CORTICOSTEROIDS AND OTHER MEDICINES THAT SUPPRESS THE IMMUNE SYSTEM. […] RITUXIMAB IS AN EFFECTIVE DRUG AND HAS FEWER RISKS THAN OTHER MEDICINES. […] CYCLOPHOSPHAMIDE IS USED IN LIFE-THREATENING CONDITIONS WHERE RITUXIMAB IS NOT WORKING OR AVAILABLE. THIS MEDICINE WAS USED MORE OFTEN IN THE PAST.

• #2 Cryoglobulinemic Vasculitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/cryoglobulinemic-vasculitis/

  Cryoglobulinemic vasculitis is a rare form of vasculitis characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. […] The cause of cryoglobulinemic vasculitis is not fully understood. More than 90 percent of cases are associated with chronic hepatitis C virus (HCV) infections, so treating hepatitis is very important. […] Treatment for cryoglobulinemic vasculitis depends on organs affected, symptom severity, and the underlying conditions. When the co-existing condition is treated, the symptoms of cryoglobulinemic vasculitis typically improve. […] For mild cases, doctors may suggest avoiding cold temperatures and treating pain with over-the-counter medications, along with regular checkups to monitor the disease. […] For moderate and severe cases, treatments may include the following: Antiviral medications are usually prescribed for those with HCV; if doctors determine that HCV is the cause of the cryoglobulinemia, you will likely be referred to a hepatologist (liver specialist).

• #2 Cryoglobulinemia: Causes, symptoms, and treatment

  https://www.medicalnewstoday.com/articles/318686

  A doctor will treat cryoglobulinemia based on the type, the severity of the damage, the parts of the body affected, and the underlying disease or condition present. […] In mild cases without symptoms, a doctor may not treat the condition at all. Instead, they may advise people to avoid cold weather or simply monitor them and recommend that they return for a further assessment if they develop any new symptoms. […] In more moderate to severe cases, a number of treatment options are available. These include: […] Corticosteroids or other immunosuppressors, which help stop the immune system from attacking healthy cells. […] Plasmapheresis, which filters out the clumps of cryoglobulins and helps prevent blocked arteries and organ damage. […] Newer biologic medications, such as rituximab (Rituxan), which is an artificial antibody that can prevent the protein forming clumps.

• #2 Cryoglobulinemia | UNC Kidney Center

  https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/cryoglobulinemia/

  What is the treatment? […] First, the underlying disease should be treated. For type I, therapy may include chemotherapy or radiation therapy for the underlying cancer. For types II and III, this may include antiviral therapy for hepatitis C. Any other illness causing the disease may need to be treated. […] Treatment of cryoglobulinemia itself depends on how severe the disease is. Mild disease, without signs of damage to the kidney or other organs, can be treated with non-steroidal anti-inflammatory drugs such as ibuprofen. For moderate or severe disease that affects the kidney or other organs, treatment includes corticosteroids (prednisone, methylprednisolone, Medrol) to reduce internal swelling. Other drugs that suppress the immune system, such as cyclophosphamide or rituximab are used as well. Plasmapheresis may also be used, which is a treatment that physically removes the cryoglobulins by filtering the blood.

• #2

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  Plasmapheresis, in conjunction with immunosuppression, can be used as adjunctive therapy to antiviral and/or rituximab therapy for patients with severe organ- or life-threatening disease. […] Cyclophosphamide use is best reserved for patients with severe disease who are unable to be treated with antiviral or rituximab therapy. […] The role of glucocorticoid use remains poorly defined, with some studies supporting moderate or high-dose prednisone use to treat active disease. […] The general approach to treatment of mixed cryoglobulinemic vasculitis is usually three-pronged: 1. Treatment of the underlying cause, such as with antiviral therapy in HCV-associated disease 2. Target circulating B cells with rituximab (or other agents) to decrease B cell production of cryoglobulins in moderate to severe disease 3. Addition of plasmapheresis in combination with intensive immunosuppression (e.g., high-dose glucocorticoids and cyclophosphamide) to remove and prevent production of circulating cryoglobulins in cases of severe, life-threatening disease.

• #2 Cryoglobulinemia: Better Treatments With Brighter Outcomes

  https://www.cancernetwork.com/view/cryoglobulinemia-better-treatments-brighter-outcomes

  The outcome for patients with cryoglobulinemia has improved since the recognition that the condition is frequently associated with HCV and that elimination of this virus has therapeutic benefit for affected patients. […] The goal of the management of type I cryoglobulinemia in the setting of malignant disease is to eliminate the malignant B-cell clone that is producing the offending Ig through the use of effective anticancer treatment. Patients with MGUS are often managed with glucocorticosteroids, although the antiB-cell antibody rituximab has been used, as has plasmapheresis; bortezomib has been tried as well. […] The treatment of patients with virally associated mixed cryoglobulinemia has focused on combination therapy with antiviral drugs to eliminate the offending HCV and its associated cryoglobulinemic-inducing proteins. Most patients receive ribavirin along with pegylated interferon-alfa, and the majority have good responses.

• #2 Cryoglobulinemia – Wikipedia

  https://en.wikipedia.org/wiki/Cryoglobulinemia

  Treatment of Type I disease is generally directed towards treating the underlying pre-malignant or malignant disorder (see plasma cell dyscrasia, Waldenstrm’s macroglobulinemia, and chronic lymphocytic leukemia). This involves appropriate chemotherapy regimens which may include bortezomib (promotes cell death by apoptosis in cells accumulating immunoglobulins) in patients with monoclonal immunoglobulin-induced kidney failure and rituximab (antibody directed against CD20 surface antigen-bearing lymphocytes) in patients with Waldenstroms macroglobulinemia. […] Treatment of mixed cryoglobulinemic disease is, similar to type I disease, directed toward treating any underlying disorder. This includes malignant (particularly Waldenstrm’s macroglobulinemia in type II disease), infectious, or autoimmune diseases in type II and III disease. Recently, evidence of hepatitis C infection has been reported in the majority of mixed disease cases with rates being 70-90% in areas with high incidences of hepatitis C. The most effective therapy for hepatitis C-associated cryoglobulinemic disease consists of a combination of anti-viral drugs, pegylated INF and ribavirin; depletion of B cells using rituximab in combination with antiviral therapy or used alone in patients refractory to antiviral therapy has also proven successful in treating the hepatitis C-associated disease. Data on the treatment of infectious causes other than hepatitis C for mixed disease are limited. A current recommendation treats the underlying disease with appropriate antiviral, anti-bacterial, or anti-fungal agents, if available; in cases refractory to an appropriate drug, the addition of immunosuppressive drugs to the therapeutic regimen may improve results. Mixed cryoglobulinemic disease associated with autoimmune disorders is treated with immunosuppressive drugs: a combination of a corticosteroid with either cyclophosphamide, azathioprine, or mycophenolate or combination of a corticosteroid with rituximab have been used successfully to treated mixed disease associated with autoimmune disorders.

• #2 Cryoglobulinemia Treatment & Management: Approach Considerations, Medical Care, Consultations

  https://emedicine.medscape.com/article/329255-treatment

  Immunosuppressive medications (eg, corticosteroid therapy and/or cyclophosphamide or azathioprine) are indicated upon evidence of organ involvement such as vasculitis, renal disease, progressive neurologic findings, or disabling skin manifestations. […] Plasmapheresis is indicated for severe or life-threatening complications related to in vivo cryoprecipitation or serum hyperviscosity. Concomitant use of high-dose corticosteroids and cytotoxic agents is recommended for reduction of immunoglobulin production. […] Pegylated interferon alfa (IFN-alfa) combined with ribavirin has demonstrated efficacy in patients with cryoglobulinemia associated with hepatitis C virus (HCV) infection, and efficacy in patients with chronic myelogenous leukemias and low-grade lymphomas has been reported. […] A Kidney Disease: Improving Global Outcomes (KDIGO) guideline on the management of HCV in patients with chronic kidney disease recommends treating patients who have severe cryoglobulinemia induced by HCV should be treated with immunosuppressive agents (generally with rituximab as the first-line agent) with or without plasma exchange, in addition to DAAs.

• #2 Essential Mixed Cryoglobulinemia: Symptoms, Treatment

  https://www.medicinenet.com/essential_mixed_cryoglobulinemia/article.htm

  What is the treatment for cryoglobulinemia? Essential mixed cryoglobulinemia is treated with combinations of medications which reduce inflammation and suppress the immune system. Medications used include nonsteroid antiinflammatory drugs (ibuprofen, aspirin, and others), steroids (prednisone, prednisolone), cyclophosphamide (Cytoxan), chlorambucil (Leukeran), and azathioprine (Imuran). Plasmapheresis (hemapheresis), a procedure whereby the blood’s serum is filtered to remove the cryoglobulins, is also performed for severe symptoms. […] Studies have demonstrated some benefit of using interferon-alpha for those patients with evidence of hepatitis C virus, particularly those with mild disease or in those with remission of manifestations after immune suppression treatment.

• #2 Cryoglobulinemia | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/20147

  Cyclophosphamide has been utilized alongside apheresis to address high cryocrit levels and prevent a post-apheresis rebound in cryoglobulin synthesis. However, its usage has diminished due to the rise of B-cell-depleting monoclonal antibodies such as rituximab. […] The apparent severity of the disease guides healthcare professionals on how best to treat the patient. […] A comprehensive treatment plan for managing mixed cryoglobulinemia typically involves pain management, wound care, and preventive measures against infections. […] In moderate-to-severe cases, the specialized focus is to address the primary symptoms with immunosuppressive therapy. Typically, immunosuppressive therapy is initiated until a steady state is achieved, followed by the devised regimen. […] Rituximab has demonstrated effectiveness in treating cryoglobulinemia by improving vasculitis, reducing RF levels, normalizing C4 complement levels, and depleting B-cell clones in both bone marrow and peripheral blood.

• #2 Cryoglobulins: An Important but Neglected Clinical Test

  https://www.annclinlabsci.org/content/36/4/395.full

  When there is evidence of organ involvement such as vasculitis, renal disease, progressive neurological findings, or disabling skin manifestations, especially in absence of HCV, cryoglobulinemia is treated by suppression of the immune response (eg, corticosteroid therapy, cyclophosphamide, azathioprine). […] Acute nephritic or nephrotic flare-ups with rapid deterioration of renal function and systemic vasculitic episodes associated with CR are treated with corticosteroids and plasmapheresis. […] Interferon-alfa (IFN) and PEG-interferon-alfa have been effective in patients with cryoglobulinemia associated with hepatitis C and in patients with chronic myelogenous leukemias and low-grade lymphomas. […] In patients with chronic hepatitis C without renal involvement, combination therapy with IFN and ribavirin (Rebetron) has been shown to be superior to IFN alone in inducing longer remission and may eradicate HCV infection in a considerable number of subjects.

• #2 Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9873783/

  Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis characterized by the proliferation of B-cell clones producing pathogenic immune complexes, called cryoglobulins. […] Recently, evidence in favor of rituximab (RTX), an anti-CD 20 monoclonal antibody, is emerging in CV: nevertheless, questions upon the safety of this therapeutic approach, especially in HCV patients, are still being issued and universally accepted recommendations that can help physicians in MCS treatment are lacking. […] A Consensus Committee provided a prioritized list of research questions to perform a systematic literature review (SLR). […] Seventeen recommendations for the management of mixed cryoglobulinemia with rituximab from the Italian Study Group of Cryoglobulinemia (GISC) were developed to give a valuable tool to the physician approaching RTX treatment in CV.

• #2

  https://link.springer.com/article/10.1007/s10067-022-06391-w

  Overall, rituximab is effective (and safe) on the severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 1A) […] For most patients with moderate to severe MCS, RTX is considered the treatment of choice whenever it is necessary to contain the proliferation of the cell clones responsible to produce cryoglobulins. […] In particular, rituximab is effective (and safe) on the glomerulonephritis of cryoglobulinemic vasculitis (LoE 2B) […] Treatment with RTX has proven to be effective in cryoglobulinemic glomerulonephritis. […] In particular, rituximab is effective (and safe) on the peripheral neuropathy of cryoglobulinemic vasculitis (LoE 2C) […] Evidence supporting RTX as an effective treatment in PNS involvement can be extracted from one RCT that included 16 participants with PNS involvement randomized at RTX administrations versus 17 patients treated with non-RTX therapy.

• #2

  https://link.springer.com/article/10.1007/s10067-022-06391-w

  Rituximab given at low doses (250 mg/mq weekly for 2 weeks) is equally effective as given at high doses (375 mg/mq/weekly for 4 weeks or 1 g 2 weeks apart) in some cases of cryoglobulinemic vasculitis (LoE 5C) […] Maintenance treatment with rituximab is required in severe or life-threatening cryoglobulinemic vasculitis (LoE 5C).

• #2

  https://link.springer.com/article/10.1007/s10067-022-06391-w

  Rituximab shows a steroid-sparing effect in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B) […] Rituximab does not usually carry an increased risk of serious adverse events compared to other immunosuppressants or high-dose glucocorticoids. […] Rituximab given alone is not associated with an increased risk of hepatitis C reactivation, even if a transient elevation of the viral load could be seen (LoE 1B) […] The risk of severe infusion reactions during rituximab administration is very low (LoE 1A) […] Rituximab is effective and safe in combination with antivirals in some cases of cryoglobulinemic vasculitis (LoE 5C) […] Rituximab is effective in patients with HCV-related cryoglobulinemic vasculitis showing persistent and severe clinical course, despite virological clearance by antivirals (LoE 5C)

• #2

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  For patients with cryoglobulinemic vasculitis, we consider treatment of the underlying disorder (if present) to be first-line therapy. […] For hepatitis C virus (HCV)-associated cryoglobulinemic vasculitis, antiviral therapy directed at HCV should be considered first-line treatment for patients who are candidates. […] Interferon-free direct acting antiviral regimens have been shown to be very effective in the treatment of chronic HCV infection and preliminary results of the use of these regimens are promising for the treatment of HCV-associated cryoglobulinemic vasculitis. […] Patients with severe life- or organ-threatening manifestations of cryoglobulinemic vasculitis may benefit by treatment with rituximab in addition and potentially prior to the initiation of antiviral therapy. […] We also recommend treatment with rituximab in patients who have a contraindication to or who have failed antivirals.

• #2 Cryoglobulinemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557606/

  However, its use comes with potential toxicities, such as life-threatening vasculitis flares, serum sickness syndrome, and exacerbation of HCV viremia. […] Presently, apheresis is considered a second-line treatment option for cryoglobulinemic vasculitis. […] However, as outlined below, apheresis is crucial in severe conditions, which include the following: Hyperviscosity syndrome (especially with a cryocrit exceeds 10%), skin ulcers caused by cutaneous vasculitis, life-threatening, multiorgan cryoglobulinemic vasculitis, rapidly progressing renal failure, refractory neuropathy. […] Steroids and cyclophosphamide are frequently administered alongside apheresis to mitigate the risk of a post-apheresis rebound in cryoglobulin production. […] Patients undergoing immunosuppressive treatments for cryoglobulinemia necessitate close monitoring, the extent of which hinges on the severity of the condition.

• #2 Cryoglobulinemia Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/cryoglobulinemia

  A TREATMENT CALLED PLASMAPHERESIS IS ALSO USED. IN THIS PROCEDURE, BLOOD PLASMA IS TAKEN OUT OF BLOOD CIRCULATION AND ABNORMAL CRYOGLOBULIN ANTIBODY PROTEINS ARE REMOVED. THE PLASMA IS REPLACED BY FLUID, PROTEIN, OR DONATED PLASMA. […] TREATMENT IS DIRECTED AGAINST THE ABNORMAL CANCER CELLS THAT PRODUCE THE CRYOGLOBULIN.

• #2 Cryoglobulinemia and Multiple Myeloma: Treatment and Outlook

  https://www.healthline.com/health/multiple-myeloma/cryoglobulinemia-and-multiple-myeloma

  Treatment for cryoglobulinemia is only necessary if you have symptoms. […] Current treatments typically focus on the underlying cancer. […] In the 2017 study of 102 people with type 1 cryoglobulinemia, 73 people received treatment. Treatment was broadly divided into the following categories: steroids alone, steroids with chemotherapy drugs called alkylating agents, the targeted therapy drug rituximab (Rituxan) with or without steroids, rituximab and alkylating agents with or without steroids, new myeloma drugs, including immunomodulatory drugs and proteasome inhibitors, other therapies, such as antimetabolites like azathioprine and methotrexate. […] The researchers in this study found that symptoms improved in about 80 percent of those who received treatment. Only 21 percent experienced no response to treatment.

• #2 Cryoglobulinemia – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557606/

  Cryoglobulinemia poses a diagnostic and therapeutic challenge due to its varied clinical manifestations. […] Treatment targets both the cryoglobulins and the underlying conditions, with options including pharmacotherapy, plasmapheresis, and management of associated diseases. […] Treatment varies based on the severity and nature of the underlying disorder, with mixed cryoglobulinemia typically treated with steroids and rituximab. […] This activity also explores current treatment options for cryoglobulinemia, including pharmacological therapies, plasmapheresis, and management of associated conditions. […] The treatment of cryoglobulinemia depends on the underlying primary disorder, severity, and nature of organ involvement. […] In presentations of mixed cryoglobulinemia with symptoms, the treatment is directed at the underlying autoimmune or infectious disorders.

• #2 Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9873783/

  Rituximab shows a steroid-sparing effect in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B). […] Rituximab does not usually carry an increased risk of serious adverse events compared to other immunosuppressants or high-dose glucocorticoids. […] Rituximab given alone is not associated with an increased risk of hepatitis C reactivation, even if a transient elevation of the viral load can be seen (LoE 1B). […] The risk of severe infusion reactions during rituximab administration is very low (LoE 1A). […] Rituximab is effective and safe in combination with antivirals in some cases of cryoglobulinemic vasculitis (LoE 5C). […] Rituximab is effective in patients with HCV-related cryoglobulinemic vasculitis showing persistent and severe clinical course, despite virological clearance by antivirals (LoE 5C). […] Maintenance treatment with rituximab is required in severe or life-threatening cryoglobulinemic vasculitis (LoE 5C).

• #2

  https://link.springer.com/article/10.1007/s10067-022-06391-w

  In particular, rituximab is effective (and safe) on the skin ulcers of cryoglobulinemic vasculitis (LoE 1A) […] B-cell depletion represents a valid choice of treatment for severe skin ulcers. […] Rituximab is equally effective on other, not severe manifestations (purpura, arthralgia, fatigue) of cryoglobulinemic vasculitis (LoE 2B) […] Rituximab is equally effective in infectious and non-infectious cryoglobulinemic vasculitis (LoE 5C) […] Rituximab should be used cautiously in patients carrying latent HBV infection, provided that an adequate prophylactic therapy for HBV infection, or monitoring HBV DNA or HBsAg title should be done (LoE 5C) […] Re-treatment at clinical relapse with rituximab, after the first cycle, is effective (and safe) in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B)

• #2 Cryoglobulinemic Vasculitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/cryoglobulinemic-vasculitis/

  Regular doctor visits and ongoing monitoring are important in detecting relapses and preventing ongoing complications. If your symptoms return or you develop new ones, report them to your doctor as soon as possible. […] Effective treatment of cryoglobulinemic vasculitis may require the coordinated efforts and ongoing care of a team of medical providers and specialists.

• #2 Cryoglobulinemic Vasculitis – Vasculitis Foundation

  https://vasculitisfoundation.org/education/vasculitis-types/cryoglobulinemic-vasculitis/

  Immunosuppressive drugs are the mainstay of treatment for severe disease where vital organs are affected. Glucocorticoids such as prednisone, azathioprine, and cyclophosphamide are widely used. […] Biologic drugs such as rituximab are a common treatment option for this condition. Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation. […] Plasmapheresis is an option when patients have life-threatening or organ-threatening cryoglobulinemic vasculitis. This procedure filters clumps of cryoglobulins from the blood plasma, helping to prevent cryoglobulins from blocking the arteries and restricting blood flow to organs. […] Relapses can occur, so follow-up care is essential. […] The medications used to treat cryoglobulinemic vasculitis have potentially serious side effects such as lowering your body’s ability to fight infection, and potential bone loss (osteoporosis), among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important.

• #2 Cryoglobulinemic Disease

  https://www.cancernetwork.com/view/cryoglobulinemic-disease

  While there remain three main broad treatment strategies for cryoglobulinemia (conventional immunosuppression, antiviral treatment, and biologic therapy), the most recent studies suggest a change in the therapeutic approach from monotherapy to combined/sequential regimens, including both etiologic- and pathologic-driven therapies, the aim of which is to block the different etiopathogenic pathways involved.

• #2 Cryoglobulinemia Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/329255-guidelines

  Rituximab should be used with caution in patients carrying latent HBV infection; Adequate prophylactic therapy for HBV infection, or monitoring HBV DNA or HBsAg title should be done. […] Rituximab does not usually carry an increased risk of serious adverse events compared to other immunosuppressants or high-dose glucocorticoids. […] Rituximab given alone is not associated with an increased risk of HCV reactivation, even if a transient elevation of the viral load is present. […] The risk of severe infusion reactions during rituximab administration is very low. […] Rituximab is effective and safe for use in combination with antivirals in some cases of cryoglobulinemic vasculitis. […] Rituximab is effective in patients with HCV-related cryoglobulinemic vasculitis showing persistent and severe clinical course.

• #2 UT Health Austin | Cryoglobulinemia

  https://uthealthaustin.org/conditions/cryoglobulinemia

  Like all forms of vasculitis, corticosteroids like prednisone can be used to address the inflammation associated with cryoglobulinemia. Your physician may also use a biologic drug called rituximab. […] At UT Health Austin, we take a multidisciplinary approach to your care. This means you will benefit from the expertise of multiple specialists across a variety of disciplines caring for you in one place. The Vasculitis Clinic care team includes rheumatologists, nurses, and medical assistants who work together to help you get back to the things in your life that matter most to you. […] We collaborate with our colleagues at the Dell Medical School and The University of Texas at Austin to utilize the latest research, diagnostic, and treatment techniques, allowing us to develop the best treatment plan for you. Advanced imaging and lab testing are also available on-site if needed, including computed tomography angiography (CTA) and magnetic resonance angiography (MRA).

• #3

  https://link.springer.com/article/10.1007/s40674-016-0048-5

  While PEG-IFN-based regimens show clinical efficacy, their inability to induce a complete clinical and virologic response in many patients indicates that other therapeutic options are needed. […] More recently, treatment options have expanded with the addition of first-generation protease inhibitors (boceprevir or telaprevir). […] Current interferon-free regimens include ledipasvir-sofosbuvir without ribavirin, elbasvir-grazoprevir with or without ribavirin, ombitasvir-paritaprevir-ritonavir plus dasabuvir with or without ribavirin, simeprevir plus sofosbuvir with or without ribavirin, and daclatasvir plus sofosbuvir. […] This favorable response profile has led to interest in the study of these regimens in patients with HCV-related cryoglobulinemic vasculitis. […] Some experts recommend delaying the initiation of antiviral therapy in patients with severe manifestations of cryoglobulinemic vasculitis for one to four months after initiation of immunosuppression.

• #3

  https://link.springer.com/article/10.1007/s10067-022-06391-w

  In particular, rituximab is effective (and safe) on the skin ulcers of cryoglobulinemic vasculitis (LoE 1A) […] B-cell depletion represents a valid choice of treatment for severe skin ulcers. […] Rituximab is equally effective on other, not severe manifestations (purpura, arthralgia, fatigue) of cryoglobulinemic vasculitis (LoE 2B) […] Rituximab is equally effective in infectious and non-infectious cryoglobulinemic vasculitis (LoE 5C) […] Rituximab should be used cautiously in patients carrying latent HBV infection, provided that an adequate prophylactic therapy for HBV infection, or monitoring HBV DNA or HBsAg title should be done (LoE 5C) […] Re-treatment at clinical relapse with rituximab, after the first cycle, is effective (and safe) in patients with severe, not immediately life-threatening, clinical manifestations of cryoglobulinemic vasculitis (LoE 2B)

• #3 Cryoglobulinemia Guidelines: Guidelines Summary

  https://emedicine.medscape.com/article/329255-guidelines

  Rituximab given at low doses (250 mg/mq weekly for 2 weeks) is equally effective as given at high doses (375 mg/mq/weekly for 4 weeks or 1 g 2 weeks apart) in selected cases of cryoglobulinemic vasculitis. […] Maintenance treatment with rituximab is required in severe or life-threatening cryoglobulinemic vasculitis.

Zobacz więcej